Publication

Precision Oncology Comes of Age: Tumor-Agnostic Approaches.

Downloadable Content

Persistent URL
Last modified
  • 05/22/2025
Type of Material
Authors
    Colleen Lewis, Emory UniversityR Donald Harvey, Emory University
Language
  • English
Date
  • 2020-04
Publisher
  • Harborside
Publication Version
Copyright Statement
  • © 2020 Harborside™
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 11
Issue
  • 3
Start Page
  • 221
End Page
  • 225
Abstract
  • Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (NTRK) fusions. Learn about the clinical trial designs that enable development of these novel therapies, and discover how testing methodologies support precision medicine advances.
Author Notes
  • Dr. Harvey has received research funding from AbbVie, Amgen, ArQule, AstraZeneca, Bristol-Myers Squibb, Boston Biomedical, Calithera, Celgene, Corvus, Eli Lilly, Five Prime Therapeutics, Genmab, Halozyme, Ignyta, Incyte, Meryx, Nektar, Pfizer, Regeneron, Rgenix, Sanofi, Syndax, Takeda, Tesaro, Vertex, and Xencor. Dr. Harvey has also served as a consultant for Takeda, Bristol-Myers Squibb, and GlaxoSmithKline. Ms. Lewis has served as a consultant for Genentech.
Keywords
Research Categories
  • Health Sciences, Oncology
  • Health Sciences, Epidemiology
  • Health Sciences, Medicine and Surgery

Tools

Relations

In Collection:

Items

Thumbnail Title File Description Date Uploaded Visibility Actions
file details Publication File - vk5bx.pdf Primary Content 2025-04-30 Public Download